Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

Table 8 Logistic regression model for factors predictive of alanine aminotransferase levels in patients with hepatitis C virus after 12 wk of protein supplementation

	Bivariate analysis		Multivariate analysis
	Crude OR (95% IC)	P value	Adjusted OR1 (95% IC)	P value
Groups
Control-casein	1		1
IG-soy	0.55 (0.29-1.04)	0.068	0.45 (0.22-0.89)	0.024
HOMA-IR
< 3.0	1		1
≥ 3.0	2.22 (1.16-4.30)	0.017	3.16 (1.51-6.93)	0.001
Gender
Male	1		1
Female	0.39 (0.20-0.77)	0.007	0.28 (0.12-0.60)	0.003
HDL-C
≥ 35 mg/dL	1		1
< 35 mg/dL	3.15 (1.37-7.76)	0.008	2.85 (1.18-7.40)	0.024

¹Adjusted for the other variables shown in the table. HOMA-IR: Homeostasis model assessment index of insulin resistance; HDL: High density lipoprotein; IG-soy: Intervention-soy; OR: Odd ratio; 95% IC: 95% confidence interval.